APA (7th ed.) Citation

C, H., E, H., M, U., M, H., G, P., R, F., . . . M, H. (2021). Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group. HemaSphere, 5(7), e600. https://doi.org/10.1097/HS9.0000000000000600

Chicago Style (17th ed.) Citation

C, Hirt, et al. "Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie Und Onkologie and the German Low-Grade Lymphoma Study Group." HemaSphere 5, no. 7 (2021): e600. https://doi.org/10.1097/HS9.0000000000000600.

MLA (9th ed.) Citation

C, Hirt, et al. "Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie Und Onkologie and the German Low-Grade Lymphoma Study Group." HemaSphere, vol. 5, no. 7, 2021, p. e600, https://doi.org/10.1097/HS9.0000000000000600.